FDA Decision on Depression Drug Causes Sage Stock to Plummet
TL;DR Summary
The split FDA decision on a new depression medicine from Sage Therapeutics and Biogen has disrupted the strategies of both companies and cast doubt on the future of their collaboration.
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
61%
77 → 30 words
Want the full story? Read the original article
Read on Barron's